Literature DB >> 31759091

Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome.

Akiko Eguchi1, Sanae Fukuda2, Hirohiko Kuratsune2, Junzo Nojima3, Yasuhito Nakatomi4, Yasuyoshi Watanabe5, Ariel E Feldstein6.   

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, debilitating disorder with a wide spectrum of symptoms, including pain, depression, and neurocognitive deterioration. Over 17 million people around the world have ME/CFS, predominantly women with peak onset at 30-50 years. Given the wide spectrum of symptoms and unclear etiology, specific biomarkers for diagnosis and stratification of ME/CFS are lacking. Here we show that actin network proteins in circulating extracellular vesicles (EVs) offer specific non-invasive biomarkers for ME/CFS. We found that circulating EVs were significantly increased in ME/CFS patients correlating to C-reactive protein, as well as biological antioxidant potential. Area under the receiver operating characteristic curve for circulating EVs was 0.80, allowing correct diagnosis in 90-94% of ME/CFS cases. From two independent proteomic analyses using circulating EVs from ME/CFS, healthy controls, idiopathic chronic fatigue, and depression, proteins identified from ME/CFS patients are involved in focal adhesion, actin skeletal regulation, PI3K-Akt signaling pathway, and Epstein-Barr virus infection. In particular, talin-1, filamin-A, and 14-3-3 family proteins were the most abundant proteins, representing highly specific ME/CFS biomarkers. Our results identified circulating EV number and EV-specific proteins as novel biomarkers for diagnosing ME/CFS, providing important information on the pathogenic mechanisms of ME/CFS.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Actin network proteins; Circulating EV; ME/CFS; Non-invasive biomarkers

Mesh:

Substances:

Year:  2019        PMID: 31759091      PMCID: PMC7010541          DOI: 10.1016/j.bbi.2019.11.015

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  52 in total

1.  Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia?

Authors:  Jesús Castro-Marrero; Mario D Cordero; Naia Sáez-Francas; Conxita Jimenez-Gutierrez; Francisco J Aguilar-Montilla; Luisa Aliste; José Alegre-Martin
Journal:  Antioxid Redox Signal       Date:  2013-05-29       Impact factor: 8.401

2.  Metabolic features of chronic fatigue syndrome.

Authors:  Robert K Naviaux; Jane C Naviaux; Kefeng Li; A Taylor Bright; William A Alaynick; Lin Wang; Asha Baxter; Neil Nathan; Wayne Anderson; Eric Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

3.  Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.

Authors:  Mary A Fletcher; Xiao R Zeng; Kevin Maher; Silvina Levis; Barry Hurwitz; Michael Antoni; Gordon Broderick; Nancy G Klimas
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240

4.  Muscle is the major source of plasma gelsolin.

Authors:  D J Kwiatkowski; R Mehl; S Izumo; B Nadal-Ginard; H L Yin
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

5.  Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome.

Authors:  Mary A Fletcher; Martin Rosenthal; Michael Antoni; Gail Ironson; Xiao R Zeng; Zachary Barnes; Jeanna M Harvey; Barry Hurwitz; Silvina Levis; Gordon Broderick; Nancy G Klimas
Journal:  Behav Brain Funct       Date:  2010-12-29       Impact factor: 3.759

6.  STRING v10: protein-protein interaction networks, integrated over the tree of life.

Authors:  Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2014-10-28       Impact factor: 16.971

7.  Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.

Authors:  H Cabanas; K Muraki; C Balinas; N Eaton-Fitch; D Staines; S Marshall-Gradisnik
Journal:  Mol Med       Date:  2019-04-23       Impact factor: 6.354

8.  Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).

Authors:  Gerwyn Morris; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

9.  Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics.

Authors:  Dorottya Nagy-Szakal; Dinesh K Barupal; Bohyun Lee; Xiaoyu Che; Brent L Williams; Ellie J R Kahn; Joy E Ukaigwe; Lucinda Bateman; Nancy G Klimas; Anthony L Komaroff; Susan Levine; Jose G Montoya; Daniel L Peterson; Bruce Levin; Mady Hornig; Oliver Fiehn; W Ian Lipkin
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

10.  Myalgic Encephalomyelitis (ME) or What? An Operational Definition.

Authors:  Frank Twisk
Journal:  Diagnostics (Basel)       Date:  2018-09-08
View more
  9 in total

1.  The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure.

Authors:  Herbert Renz-Polster; Marie-Eve Tremblay; Dorothee Bienzle; Joachim E Fischer
Journal:  Front Cell Neurosci       Date:  2022-05-09       Impact factor: 6.147

Review 2.  Role of ATP in Extracellular Vesicle Biogenesis and Dynamics.

Authors:  Marta Lombardi; Martina Gabrielli; Elena Adinolfi; Claudia Verderio
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

3.  Cytokine profiling of extracellular vesicles isolated from plasma in myalgic encephalomyelitis/chronic fatigue syndrome: a pilot study.

Authors:  Ludovic Giloteaux; Adam O'Neal; Jesús Castro-Marrero; Susan M Levine; Maureen R Hanson
Journal:  J Transl Med       Date:  2020-10-12       Impact factor: 5.531

Review 4.  Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Authors:  Klaus J Wirth; Carmen Scheibenbogen
Journal:  J Transl Med       Date:  2021-04-21       Impact factor: 5.531

Review 5.  Insights into Metabolite Diagnostic Biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Emi Yamano; Yasuyoshi Watanabe; Yosky Kataoka
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

6.  In-Depth Analysis of the Plasma Proteome in ME/CFS Exposes Disrupted Ephrin-Eph and Immune System Signaling.

Authors:  Arnaud Germain; Susan M Levine; Maureen R Hanson
Journal:  Proteomes       Date:  2021-01-29

7.  Comparative Analysis of Extracellular Vesicles in Patients with Severe and Mild Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Hector Bonilla; Dylan Hampton; Erika G Marques de Menezes; Xutao Deng; José G Montoya; Jill Anderson; Philip J Norris
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

8.  Phenotypic characteristics of peripheral immune cells of Myalgic encephalomyelitis/chronic fatigue syndrome via transmission electron microscopy: A pilot study.

Authors:  Fereshteh Jahanbani; Rajan D Maynard; Justin Cyril Sing; Shaghayegh Jahanbani; John J Perrino; Damek V Spacek; Ronald W Davis; Michael P Snyder
Journal:  PLoS One       Date:  2022-08-09       Impact factor: 3.752

9.  Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population.

Authors:  Toshimori Kitami; Sanae Fukuda; Tamotsu Kato; Kouzi Yamaguti; Yasuhito Nakatomi; Emi Yamano; Yosky Kataoka; Kei Mizuno; Yuuri Tsuboi; Yasushi Kogo; Harukazu Suzuki; Masayoshi Itoh; Masaki Suimye Morioka; Hideya Kawaji; Haruhiko Koseki; Jun Kikuchi; Yoshihide Hayashizaki; Hiroshi Ohno; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.